Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis R&D

This article was originally published in The Tan Sheet

Executive Summary

Novartis has opened an OTC Research & Development center in Mumbai, India that is "currently working on various conventional and innovative dosage forms," the company announces Feb. 22. The center increases the firm's pharmaceutical development capacity by around 25%, the firm said. Novartis runs two other centers in Nyon, Switzerland and Lincoln, Neb. (1"The Tan Sheet" Oct. 21, 1996, p. 10). The facility will develop OTC drugs, including products for cough/cold, allergies, smoking cessation, gastrointestinal disorders, dermal infections and nutritional supplements. The center employs 35 associates, draws on the "expertise and skills" available in the country and "expands the company's presence in a country that is rapidly becoming a dominant force in the international marketplace," Novartis states...

You may also be interested in...



Novartis Self-Medication's lead OTC manufacturing facility will be in Lincoln, Neb.

NOVARTIS SELF-MEDICATION MANUFACTURING WILL BE BASED IN LINCOLN, NEB. following the merger of Ciba-Geigy and Sandoz, the companies announced Oct. 17. The Sandoz manufacturing site in Lincoln will absorb the majority of the OTC production currently handled by Ciba's facility in Fort Washington, Pa.

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel